Summary
Most claims provided are not assessable against the supplied label excerpts (only absorption/GI motility PK excerpts were provided). Claims about emergency contraception indications, dosing regimens, mechanisms of action, timing effectiveness, pregnancy intent, and specific drug interaction examples are unsupported by the supplied prescribing-information text.
Category Scores
Accurate Statements
Absorption: Levonorgestrel is rapidly and completely absorbed after oral administration (~100% bioavailability) and is not subject to first-pass metabolism or enterohepatic circulation; diarrhea/vomiting may reduce hormone absorption.
SECTION 12: “Levonorgestrel is rapidly and completely absorbed... (bioavailability about 100%). Levonorgestrel is not subject to first-pass metabolism or enterohepatic circulation...” ; SECTION 9: “Diarrhea and/or vomiting may reduce hormone absorption.”
Unsupported Statements
Levonest is a brand name for levonorgestrel.
Not supported by the provided excerpts. The provided product description indicates Levonest contains levonorgestrel and ethinyl estradiol, so this statement is incomplete/uncorroborated by the excerpts.
Levonorgestrel is a synthetic progestin hormone.
No support in the provided excerpts.
Levonest products may be marketed for emergency contraception or other hormone-related uses depending on the country and manufacturer.
No label excerpt provided addressing marketing indications by country/manufacturer.
In many markets, levonorgestrel brand products like Levonest are used as emergency contraception.
No label excerpt provided addressing emergency contraception indication or market usage.
Emergency levonorgestrel emergency contraception works by delaying ovulation when taken as soon as possible after unprotected sex.
No mechanism of action excerpt provided.
The effectiveness of levonorgestrel emergency contraception decreases the longer you wait after unprotected sex.
No effectiveness/timing excerpt provided.
Dosing instructions for Levonest depend on the specific Levonest version (tablet strength) and whether it is a single-dose or two-dose regimen.
No dosing/regimen excerpt provided.
Emergency levonorgestrel products are taken as soon as possible after intercourse, following the package directions or clinician advice.
No administration/dosing excerpt provided.
Common side effects of levonorgestrel emergency contraception include nausea, headache, dizziness, breast tenderness, and fatigue.
No adverse reactions excerpt provided.
Changes to the next menstrual period are common with levonorgestrel emergency contraception, including earlier or later bleeding or spotting.
No adverse reactions/menstrual effects excerpt provided.
Emergency contraception with levonorgestrel is intended for people who are not already pregnant.
No indication/pregnancy intent excerpt provided.
Levonorgestrel emergency contraception is not used to end an existing pregnancy.
No label excerpt provided stating this.
Some medications can reduce levonorgestrel effectiveness.
No label excerpt provided addressing effectiveness reduction for levonorgestrel in emergency contraception context.
Certain enzyme-inducing drugs, including some anti-seizure medications, can reduce levonorgestrel effectiveness.
No specific enzyme-inducing/anti-seizure medication details were provided in the excerpts.
Rifampin or rifabutin can reduce levonorgestrel effectiveness.
No rifampin/rifabutin-specific interaction excerpt provided.
Levonorgestrel emergency contraception effectiveness depends heavily on how quickly it is taken after unprotected sex.
No effectiveness/timing excerpt provided.
Earlier use of levonorgestrel emergency contraception gives better odds of preventing pregnancy.
No effectiveness/pregnancy prevention probability excerpt provided.
Contradictions
Important Omissions
Label-based indication, dosing/regimen, contraindications, warnings/precautions, contraindications, and specific drug interaction guidance for Levonest were not provided in the supplied label excerpts, so those safety/administration details cannot be evaluated.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Only absorption/GI motility support could be verified from the supplied excerpts. Most other claims are unsupported due to missing label content, so overall alignment is limited; however, no direct contradictions to the provided excerpts were identified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Major portions of the AI claims (indication, dosing, mechanism, effectiveness timing, pregnancy intent, adverse reactions, and specific interaction examples) are not supported by the provided prescribing-information excerpts.
Suggested Improvement
Limit claims to what is explicitly supported by the supplied label text (e.g., levonorgestrel absorption and GI effects on absorption) or provide the corresponding FDA label sections (Indications, Dosage and Administration, Clinical Studies/Mechanism, Warnings/Precautions, Adverse Reactions, and Drug Interactions) for evaluation and accurate on-label summarization.